

any interstate or intrastate telecommunications service. The Commission's consideration of preemption under section 253 typically begins with the filing of a petition by an aggrieved party. The Commission typically places such petitions on public notice and requests comment by interested parties. The Commission's decision is based on the public record, generally composed of the petition and comments. The Commission has considered a number of preemption items since the passage of the Telecommunications Act of 1996, and believes it is in the public interest to inform the public of the information necessary for full consideration of the issues likely to be involved in section 253 preemption actions. In order to render a timely and informed decision, the Commission expects petitioners and commenters to provide it with relevant information sufficient to describe the legal regime involved in the controversy and to provide the factual information necessary for a decision.

Federal Communications Commission.

**Marlene H. Dortch,**

*Secretary, Office of the Secretary, Office of the Managing Director.*

[FR Doc. 2015-00680 Filed 1-16-15; 8:45 am]

**BILLING CODE 6712-01-P**

## FEDERAL ELECTION COMMISSION

### Sunshine Act Meeting

**AGENCY:** Federal Election Commission.

**DATE AND TIME:** Tuesday, January 13, 2015 at 10:00 a.m. and its continuation on Thursday January 15, 2015 at the conclusion of the Open Meeting.

**PLACE:** 999 E Street NW., Washington, DC.

**STATUS:** This meeting will be closed to the public.

**Federal Register Citation of Previous Announcement—80 FR 1030 (January 8, 2015)**

This meeting will be continued on February 10, 2015.

\* \* \* \* \*

**PERSON TO CONTACT FOR INFORMATION:** Judith Ingram, Press Officer, Telephone: (202) 694-1220.

**Shelley E. Garr,**

*Deputy Secretary of the Commission.*

[FR Doc. 2015-00905 Filed 1-15-15; 4:15 pm]

**BILLING CODE 6715-01-P**

## FEDERAL RETIREMENT THRIFT INVESTMENT BOARD

### Sunshine Act; Notice of Meeting

**TIME AND DATE:** 8:30 a.m. (Eastern Time) January 26, 2015.

**PLACE:** 10th Floor Board Meeting Room, 77 K Street NE., Washington, DC 20002.

**STATUS:** Parts will be open to the public and parts will be closed to the public.

#### MATTERS TO BE CONSIDERED:

##### Open to the Public

1. Approval of the Minutes of the December 15, 2014 Board Member Meeting
2. Leadership Development Program
3. Thrift Savings Plan Reports
  - a. Monthly Participant Activity Report
  - b. Quarterly Investment Policy Report
  - c. Legislative Report
  - d. Vendor Financials
  - e. Audit Status
  - f. Budget Review
4. Annual Expense Ratio Review
5. Project Prioritization Overview
6. Enterprise Risk Assessment

##### Closed to the Public

7. Litigation

#### CONTACT PERSON FOR MORE INFORMATION:

Kimberly Weaver, Director, Office of External Affairs, (202) 942-1640.

DATE: January 15, 2015.

**James Petrick,**

*General Counsel, Federal Retirement Thrift Investment Board.*

[FR Doc. 2015-00921 Filed 1-15-15; 4:15 pm]

**BILLING CODE 6760-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Decision to Evaluate a Petition To Designate a Class of Employees From the Lawrence Livermore National Laboratory in Livermore, California, To Be Included in the Special Exposure Cohort

**AGENCY:** National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention, Department of Health and Human Services.

**ACTION:** Notice.

**SUMMARY:** NIOSH gives notice as required by 42 CFR 83.12(e) of a decision to evaluate a petition to designate a class of employees from the Lawrence Livermore National Laboratory in Livermore, California, to be included in the Special Exposure Cohort under the Energy Employees Occupational Illness Compensation

Program Act of 2000. The initial proposed definition for the class being evaluated, subject to revision as warranted by the evaluation, is as follows:

*Facility:* Lawrence Livermore National Laboratory.

*Location:* Livermore, California.

*Job Titles and/or Job Duties:* All employees of the Department of Energy, its predecessor agencies, and its contractors and subcontractors who worked in any area.

*Period of Employment:* January 1, 1974 through December 31, 1995.

#### FOR FURTHER INFORMATION CONTACT:

Stuart L. Hinnefeld, Director, Division of Compensation Analysis and Support, National Institute for Occupational Safety and Health, 1090 Tusculum Avenue, MS C-46, Cincinnati, OH 45226-1938, Telephone 877-222-7570. Information requests can also be submitted by email to [DCAS@CDC.GOV](mailto:DCAS@CDC.GOV).

**John Howard,**

*Director, National Institute for Occupational Safety and Health.*

[FR Doc. 2015-00685 Filed 1-16-15; 8:45 am]

**BILLING CODE 4163-19-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Office of the Secretary

#### Findings of Research Misconduct

**AGENCY:** Office of the Secretary, HHS.

**ACTION:** Notice.

**SUMMARY:** Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case:

*Bin Kang, Ph.D., Oklahoma Medical Research Foundation:* Based on the Respondent's admission, an assessment conducted by the Oklahoma Medical Research Foundation (OMRF), and additional analysis conducted by ORI in its oversight review, ORI found that Dr. Bin Kang, Postdoctoral Fellow, Immunobiology and Cancer Research Program, OMRF, engaged in research misconduct in research supported by National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), grants AI056129 and AI104057.

ORI and OMRF found that Respondent engaged in research misconduct by reporting falsified data in:

- "Asb2 regulates the activity of SCF E3 ubiquitin ligases by antagonizing CAND1-mediated exchange of F-box proteins," submitted to *Molecular Cell* on June 26, 2014; hereafter referred to as the "original *Molecular Cell* manuscript"

• the revised version of “Asb2 regulates the activity of SCF E3 ubiquitin ligases by antagonizing CAND1-mediated exchange of F-box proteins,” submitted to *Molecular Cell* on September 29, 2014; hereafter referred to as the “revised *Molecular Cell* manuscript”

• grant application CA189216-01 submitted to the National Cancer Institute (NCI), NIH; hereafter referred to as the “original NCI grant application”

• grant application CA189216-01A1 submitted to NCI, NIH; hereafter referred to as the “revised NCI grant application”

ORI found that Respondent knowingly falsified and/or fabricated Western blot gel images by duplication, reuse and relabeling, and/or alteration through contrast, rotation, and/or scale of the images.

Specifically, Respondent included falsified images in all of the figures (Figures 1-6 and S1-5) in the original *Molecular Cell* manuscript, all of the figures (Figures 1-6 and S1-7) in the revised

*Molecular Cell* manuscript, Figures 2-4, 9, and 11 in the original NCI grant application, and Figures 3-5, 10, and 11 in the revised NCI grant application.

Dr. Kang has entered into a Voluntary Settlement Agreement (Agreement) and has voluntarily agreed for a period of three (3) years, beginning on December 23, 2014:

(1) To have his research supervised; Respondent agreed to ensure that prior to the submission of an application for U.S. Public Health Service (PHS) support for a research project on which the Respondent’s participation is proposed and prior to Respondent’s participation in any capacity on PHS-supported research, the institution employing him must submit a plan for supervision of his duties to ORI for approval; the plan for supervision must be designed to ensure the scientific integrity of Respondent’s research contribution; Respondent agreed that he will not participate in any PHS-supported research until such a supervision plan is submitted to and approved by ORI; Respondent agreed to maintain responsibility for compliance with the agreed upon plan for supervision;

(2) that any institution employing him must submit, in conjunction with each application for PHS funds, or report, manuscript, or abstract involving PHS-supported research in which Respondent is involved, a certification to ORI that the data provided by Respondent are based on actual experiments or are otherwise legitimately derived and that the data,

procedures, and methodology are accurately reported in the application, report, manuscript, or abstract; and

(3) to exclude himself voluntarily from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.

**FOR FURTHER INFORMATION CONTACT:**

Acting Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453-8200.

**Donald Wright,**

*Acting Director, Office of Research Integrity.*

[FR Doc. 2015-00802 Filed 1-16-15; 8:45 am]

**BILLING CODE 4150-31-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Office of the Secretary; Office of Medicare Hearings and Appeals; Statement of Organization, Functions, and Delegations of Authority**

Part A, Office of the Secretary, Statement of Organization, Functions, and Delegations of Authority for the Department of Health and Human Services, is being amended at Chapter AK, Office of Medicare Hearings and Appeals (OMHA), as last amended at 70 FR 36386-36387, dated June 23, 2005, and most recently at 76 FR 19995 (Apr. 11, 2011) as follows:

I. Under Section AK.10, Organization, delete the bullets and sub-bullets after the phrase, “OMHA consists of the following components,” and replace with the following:

• Medicare Hearings and Appeals Chief Judge’s Office (CJO) (Headquarters Office)

— Office of Operations

— Office of Programs

• Medicare Hearings and Appeals Field Offices

II. Under Section AK.20, Functions, Paragraph B, replace “Medicare Hearings and Appeals Field Offices (AKB1-4)” with “Medicare Hearings and Appeals Field Offices.”

III. Under Section AK.20, Functions, Paragraph B, “Medicare Hearings and Appeals Field Offices,” replace all references to the “Managing Administrative Law Judge (MALJ)” with “Associate Chief Administrative Law Judge (ACALJ).”

Dated: January 13, 2015.

**E.J. Holland, Jr.,**

*Assistant Secretary for Administration (ASA).*

[FR Doc. 2015-00743 Filed 1-16-15; 8:45 am]

**BILLING CODE 4150-24-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Medicare & Medicaid Services**

[CMS-3303-FN]

**Medicare and Medicaid Programs; Continued Approval of the Accreditation Commission for Health Care, Inc.; Home Health Agency Accreditation Program**

**AGENCY:** Centers for Medicare and Medicaid Services, HHS.

**ACTION:** Final notice.

**SUMMARY:** This final notice announces our decision to approve the Accreditation Commission for Health Care, Inc., (ACHC) for continued recognition as a national accrediting organization for home health agencies (HHAs) that wish to participate in the Medicare or Medicaid programs. An HHA that participates in Medicaid must also meet the Medicare conditions for participation (CoPs) as required under 42 CFR 488.6(b).

**DATES:** This final notice is effective February 24, 2015 through February 24, 2021.

**FOR FURTHER INFORMATION CONTACT:** Cindy Melanson, (410) 786-0310, or Patricia Chmielewski, (410) 786-6899.

**SUPPLEMENTARY INFORMATION:**

**I. Background**

A healthcare provider may enter into an agreement with Medicare to participate in the program as a HHA provided certain requirements are met. Sections 1861(o) and 1891 of the Social Security Act (the Act), establish distinct criteria for facilities seeking designation as a HHA. Regulations concerning Medicare provider agreements in general are at 42 CFR part 489 and those pertaining to the survey and certification for Medicare participation of providers and certain types of suppliers are at part 488. The regulations at part 484 specify the specific conditions that a provider must meet to participate in the Medicare program as an HHA.

Generally, to enter into a Medicare provider agreement, a facility must first be certified as complying with the conditions set forth in part 484 and recommended to us for participation by